KALA BIO, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
KALA BIO filed Form 8-K on 2026-08-28 reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, with transfer of listing mentioned. No specific dollar amounts, counterparties, or remediation details are disclosed in the header/metadata provided. The filing indicates the company has violated exchange continued listing requirements.
Why this rating
Delisting is existential for a $24.6M public company; loss of exchange listing destroys shareholder value, liquidity, and market access. Business-altering event.
Extracted items
Tradability signal
SHORT
conviction 56/100 · expected -2.66% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (5 in this cell) moved +15.95% in the called direction over 4 hrs; shrunk for sample size that's a +2.66% edge. Price is up 3.6% since the filing hit EDGAR — market hasn't digested it yet. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.80 ▼ 3.51% | at our read · backfill $0.82 | +4 hrs · backfill $0.75 ▼ 8.40% |
The stock had already moved +3.64% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.